Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 1
2004 2
2005 2
2006 4
2007 4
2011 1
2012 1
2013 2
2014 1
2015 4
2016 2
2017 1
2018 3
2019 3
2020 7
2021 5
2022 2
2024 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Results by year

Filters applied: . Clear all
Page 1
The value of plasma hypoxia markers for predicting imaging-based hypoxia in patients with head-and-neck cancers undergoing definitive chemoradiation.
Rühle A, Grosu AL, Wiedenmann N, Ruf J, Bieber B, Stoian R, Thomsen AR, Gkika E, Vaupel P, Baltas D, Weber WA, Mix M, Nicolay NH. Rühle A, et al. Among authors: wiedenmann n. Clin Transl Radiat Oncol. 2022 Feb 21;33:120-127. doi: 10.1016/j.ctro.2022.02.008. eCollection 2022 Mar. Clin Transl Radiat Oncol. 2022. PMID: 35243023 Free PMC article.
Lymphocyte Infiltration Determines the Hypoxia-Dependent Response to Definitive Chemoradiation in Head-and-Neck Cancer: Results from a Prospective Imaging Trial.
Nicolay NH, Rühle A, Wiedenmann N, Niedermann G, Mix M, Weber WA, Baltas D, Werner M, Kayser G, Grosu AL. Nicolay NH, et al. Among authors: wiedenmann n. J Nucl Med. 2021 Apr;62(4):471-478. doi: 10.2967/jnumed.120.248633. Epub 2020 Aug 28. J Nucl Med. 2021. PMID: 32859699 Free PMC article. Clinical Trial.
Immunohistochemistry-based hypoxia-immune prognostic classifier for head-and-neck cancer patients undergoing chemoradiation - Post-hoc analysis from a prospective imaging trial.
Rühle A, Grosu AL, Wiedenmann N, Stoian R, Haehl E, Zamboglou C, Baltas D, Werner M, Kayser G, Nicolay NH. Rühle A, et al. Among authors: wiedenmann n. Radiother Oncol. 2021 Jun;159:75-81. doi: 10.1016/j.radonc.2021.03.014. Epub 2021 Mar 19. Radiother Oncol. 2021. PMID: 33753155 Clinical Trial.
Interleukin-6 as surrogate marker for imaging-based hypoxia dynamics in patients with head-and-neck cancers undergoing definitive chemoradiation-results from a prospective pilot trial.
Rühle A, Wiedenmann N, Fennell JT, Mix M, Ruf J, Stoian R, Thomsen AR, Vaupel P, Baltas D, Grosu AL, Nicolay NH. Rühle A, et al. Among authors: wiedenmann n. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1650-1660. doi: 10.1007/s00259-021-05602-x. Epub 2021 Nov 13. Eur J Nucl Med Mol Imaging. 2022. PMID: 34773163 Free PMC article. Clinical Trial.
18F-FMISO-PET Hypoxia Monitoring for Head-and-Neck Cancer Patients: Radiomics Analyses Predict the Outcome of Chemo-Radiotherapy.
Carles M, Fechter T, Grosu AL, Sörensen A, Thomann B, Stoian RG, Wiedenmann N, Rühle A, Zamboglou C, Ruf J, Martí-Bonmatí L, Baltas D, Mix M, Nicolay NH. Carles M, et al. Among authors: wiedenmann n. Cancers (Basel). 2021 Jul 9;13(14):3449. doi: 10.3390/cancers13143449. Cancers (Basel). 2021. PMID: 34298663 Free PMC article.
38 results